CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 enrolled
Drug / intervention
UCB0942 +2 moredrug
Likely dose
UCB0942 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02495844
NCT02495844Phase 2Completed
CompareCT.gov

Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy.

UCB Biopharma S.P.R.L.·interventional·Posted Jul 13, 2015·Updated Feb 5, 2019

In Brief

A Phase 2 clinical trial evaluating UCB0942 and Placebo for Highly Drug-resistant Focal Epilepsy. Completed, enrolled 55 participants across 18 sites in 6 countries.

Detailed Summary

This study is to assess the efficacy, safety, and tolerability of the investigational drug UCB0942in adult subjects with drug-resistant focal epilepsy across multiple centers in Europe.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHighly Drug-resistant Focal Epilepsy
CountriesBelgium, Bulgaria, Germany, Hungary, Netherlands, Spain
CollaboratorsPRA Health Sciences

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 13, 2015
Enrollment StartJul 1, 2015
Primary CompletionFeb 1, 2017
Study CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.0 years ago

Interventions

UCB0942drug

Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use

UCB0942drug

Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use

Placebodrug

Pharmaceutical form: Film-coated tablet Route of administration: Oral use